Study of SA+X in the Treatment of Newly Diagnosed AML

NCT07548710 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: SAXUM_2026
• Study Type: interventional
• Target: 205
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with newly diagnosed acute myeloid leukemia (AML). Eligible participants will be stratified into different treatment arms based on genetic background (FLT3/IDH1 mutation status) and fitness for intensive chemotherapy. All participants will receive sonrotoclax with dose escalation from 20 mg/day to 320 mg/day, followed by maintenance dosing, which may be temporarily held by the investigator from Day 14 to Day 28 of each 28-day cycle based on the participant's condition, combined with azacitidine 75 mg/m²/day intravenously on Days 1-7. For participants fit for intensive chemotherapy, additional anthracycline (daunorubicin 60 mg/m²/day or idarubicin 10 mg/m²/day on Days 1-3) will be administered. For participants with FLT3 mutations, gilteritinib 80 mg once daily on Days 1-14 will be added; for those with IDH1 mutations, ivosidenib 500 mg once daily on Days 1-28 will be added.

Conditions

Acute Myeloid Leukemia

Keywords

Newly Diagnosed Adult Acute Myeloid Leukemia; Sonrotoclax; Azacitidine

Outcome Measures

Primary Outcomes (1)

• Composite Complete Remission

  At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

Secondary Outcomes (6)

• Minimal Residual Disease (MRD) Negativity Rate

  At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

• Overall Response Rate

  At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

• Overall Survival

  Time from enrollment to all-cause death within 3 years

• Event-free Survival

  Time from enrollment to treatment failure, relapse, or death from any cause within 3 years

• Adverse Events

  From the start of induction to 30 days after the completion of treatment

Study Arms (4)

SA+Anthracycline

EXPERIMENTAL

Drug: Anthracycline; Drug: Sonrotoclax; Drug: Azacitidine (AZA)

SA+FLT3 inhibitor

EXPERIMENTAL

Drug: Gilteritinib; Drug: Sonrotoclax; Drug: Azacitidine (AZA)

SA+IDH1 inhibitor

EXPERIMENTAL

Drug: Ivosidenib; Drug: Sonrotoclax; Drug: Azacitidine (AZA)

SA

EXPERIMENTAL

Drug: Sonrotoclax; Drug: Azacitidine (AZA)

Interventions

Anthracycline DRUG

For FLT3/IDH1 wild-type participants who are eligible for chemotherapy, Anthracycline: Daunorubicin (DNR) 60 mg/m² per day on Days 1-3, or Idarubicin (IDA) 10 mg/m² per day on Days 1-3.

SA+Anthracycline

Ivosidenib DRUG

For IDH1 mutant participants, IDH1 inhibitor (IDH1i): Ivosidenib 500 mg once daily on Days 1-28.

SA+IDH1 inhibitor

Gilteritinib DRUG

For FLT3 mutant participants, FLT3 inhibitor (FLT3i): Gilteritinib 80 mg once daily on Days 1-14.

SA+FLT3 inhibitor

Sonrotoclax DRUG

For all the participants who are eligible for this trial, Sonrotoclax (SON): 20 mg/day on Day 1, 40 mg/day on Day 2, 80 mg/day on Day 3, 160 mg/day on Day 4, and 320 mg/day on Days 5-28 of a 28-day cycle; the administration of SON may be temporarily held by the investigator from Day 14 to Day 28 based on the participant's condition.

SA; SA+Anthracycline; SA+FLT3 inhibitor; SA+IDH1 inhibitor

Azacitidine (AZA) DRUG

For all the participants who are eligible for this trial, Azacitidine (AZA): 75 mg/m² per day on Days 1-7.

SA; SA+Anthracycline; SA+FLT3 inhibitor; SA+IDH1 inhibitor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Newly diagnosed AML confirmed by bone marrow morphology and immunophenotyping (5th edition WHO diagnostic criteria)
• Subjects with APL excluded according to fusion gene and chromosome results
• ECOG performance status 0-3
• Age ≥ 18 years
• White blood cell count must be \< 25 × 10⁹/L at the start of study treatment (can be reduced by leukapheresis and/or hydroxyurea)
• Subjects must have adequate organ function, defined as follows: Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), unless elevated due to leukemic organ involvement; serum total bilirubin \< 3 × ULN; higher levels are acceptable if attributable to ineffective erythropoiesis, leukemic organ involvement, or Gilbert syndrome; serum creatinine \< 3 × ULN, or estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
• Written informed consent obtained from the subject or legal representative

You may not qualify if:

• FAB classification as M3, or molecularly confirmed APL
• Refractory / relapsed subjects
• Subjects with a history of myeloproliferative neoplasms (MPN);
• Subjects with a history of myelodysplastic syndromes (MDS);
• Subjects with a history of chronic myeloid leukemia (CML);
• Subjects with mixed phenotype acute leukemia (MPAL);
• Documented central nervous system leukemia; or documented extramedullary leukemia (e.g., myeloid sarcoma, skin infiltration), excluding liver, spleen, and lymph node involvement;
• Hypersensitivity or allergy to any of the study drugs;
• Physical conditions or organ system dysfunction that impairs the ability to swallow capsules or tablets, or significantly affects gastrointestinal function and/or absorption (including malabsorption syndrome, small bowel resection, or uncontrolled inflammatory bowel disease);
• Cardiac conditions meeting any of the following:a) Long QT syndrome or QTc interval \> 480 ms;b) Second- or third-degree atrioventricular block; severe, uncontrolled arrhythmia requiring medical treatment;c) History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other treatable arrhythmia, clinically significant pericardial disease within 6 months prior to enrollment; or electrocardiographic evidence of acute ischemia or active conduction system abnormalities;
• Previous or current concurrent malignancy other than adequately controlled non-melanoma skin basal cell carcinoma, in situ breast/cervical carcinoma, or other malignancies adequately controlled without treatment for more than 6 months;
• Significantly abnormal liver or renal function (serum bilirubin, AST, ALT, or serum creatinine \> 3 × upper limit of normal; excluding those deemed by the investigator to be related to AML);
• Subjects who have received previous anti-AML therapies other than hydroxyurea for cytoreduction, including but not limited to BCL-2, FLT3, IDH1 inhibitors, or other investigational agents;
• Coagulopathy unrelated to AML;
• HIV infection, syphilis infection, HCV infection, or active HBV infection (HBsAg positive; or HBsAg negative / HBcAb positive with HBV DNA \> 1.0 × ULN);

Sponsors & Collaborators

• Ruijin Hospital: lead

Study Sites (1)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Anthracyclines; ivosidenib; gilteritinib; Azacitidine

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates; Aza Compounds; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides

Central Study Contacts

Yang Shen

CONTACT

+86-021-64370045; sy_clinicaltrial@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: April 14, 2026
• First Posted: April 23, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 31, 2027
• Study Completion (Estimated): December 21, 2028
• Last Updated: April 23, 2026

Record last verified: 2026-04

Locations

CN (1)